Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-011 in healthy volunteers
NCT05387499Phase 1Completed
- Sponsor
- NEXEL Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NP-011 in myocardial infarction (MI) (3 arms), sponsored by NEXEL Co., Ltd. Primary endpoint: Incidence, nature and severity of adverse events up to 56 days. Started Jun 2022; status: completed.
02
Drugs
NP-011
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05387499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387499.